MXPA02005667A - Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. - Google Patents

Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.

Info

Publication number
MXPA02005667A
MXPA02005667A MXPA02005667A MXPA02005667A MXPA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A
Authority
MX
Mexico
Prior art keywords
lycoramine
galanthamine
analogs
modulators
nicotinic receptors
Prior art date
Application number
MXPA02005667A
Other languages
English (en)
Inventor
Bonnie Davis
Original Assignee
Bonnie Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonnie Davis filed Critical Bonnie Davis
Publication of MXPA02005667A publication Critical patent/MXPA02005667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Toxicology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los analogos de galantamina y licoramina son utiles en la modulacion de los receptores nicotinicos en humanos y otros animales. La modulacion de estos receptores es util en el tratamiento y/o prevencion de una variedad de condiciones que incluyen el tratamiento de trastornos de la atencion, la provision de ayuda a fumadores y en el tratamiento de la enfermedad de Parkinson.
MXPA02005667A 1999-12-10 2000-12-07 Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. MXPA02005667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17003699P 1999-12-10 1999-12-10
PCT/US2000/042654 WO2001043697A2 (en) 1999-12-10 2000-12-07 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors

Publications (1)

Publication Number Publication Date
MXPA02005667A true MXPA02005667A (es) 2004-09-10

Family

ID=22618278

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005667A MXPA02005667A (es) 1999-12-10 2000-12-07 Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.

Country Status (7)

Country Link
US (1) US6670356B2 (es)
EP (2) EP1237524A4 (es)
JP (2) JP2003516947A (es)
AU (1) AU780012B2 (es)
CA (1) CA2393301A1 (es)
MX (1) MXPA02005667A (es)
WO (1) WO2001043697A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
WO2005041979A1 (en) * 2003-10-30 2005-05-12 University Of South Florida Modulation of microglial by nicotinic medications
US20050277626A1 (en) * 2004-05-27 2005-12-15 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
PL2813225T3 (pl) * 2004-09-24 2018-11-30 University Of Maryland, Baltimore Sposób leczenia zatrucia związkami fosforoorganicznymi
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
PL2137192T3 (pl) 2008-04-14 2014-07-31 Neurodyn Life Sciences Inc Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi
RU2012106605A (ru) * 2009-07-23 2013-08-27 ШАЙЕ ЭлЭлСи Аминокислотные и пептидные пролекарства галантамина и их применение
CN103812706A (zh) * 2014-02-26 2014-05-21 国家电网公司 异构厂家数据网网络接口适配方法
US20170182058A1 (en) * 2014-03-25 2017-06-29 Emicipi Llc Treatment of rett syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
WO1988008708A1 (en) 1987-05-04 1988-11-17 Bonnie Davis Compounds for the treatment of alzheimer's disease
DK0584185T3 (da) 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
US20030050281A1 (en) 2003-03-13
WO2001043697A2 (en) 2001-06-21
AU4520701A (en) 2001-06-25
CA2393301A1 (en) 2001-06-21
EP1237524A2 (en) 2002-09-11
AU780012B2 (en) 2005-02-24
EP1237524A4 (en) 2004-06-30
US6670356B2 (en) 2003-12-30
JP2012246297A (ja) 2012-12-13
WO2001043697A3 (en) 2002-01-10
EP2311463A1 (en) 2011-04-20
JP2003516947A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
ATE216879T1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
AU2002320052A8 (en) Kcnmas as modifiers of the p53 pathway and methods of use
DE50312005D1 (de) Medizinische Vorrichtung zur Modulation neuronaler Aktivität im Gehirn
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
MXPA02005667A (es) Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69814394D1 (de) Verwendung von levobupivacain
AU2173400A (en) Method for administering agents to the central nervous system
WO2003087159A3 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
FI973023A0 (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
ATE480297T1 (de) Elektrisches stimulationssystem zur behandlung von phantomgliederschmerzen
WO2001021647A3 (en) Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
BG105275A (en) Tan-1057 derivatives
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
WO1999016406A3 (en) Therapeutic method
SE9904863D0 (sv) New use
AU1521501A (en) Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
MX9804576A (es) Composiciones que contienen bismuto, para la prevencion y tratamiento de trastornos gastrointestinales.
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
WO2002019964A3 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
MX9804579A (es) Composiciones que contienen bismuto para la prevencion y tratamiento de trastornos gastrointestinales.

Legal Events

Date Code Title Description
FG Grant or registration